Skip to Content

AD/PD 2026: Targeting Toxic Proteins in Alzheimer’s Drug Development

In Alzheimer’s disease, toxic proteins such as tau accumulate as clearance declines. In this MEDtalk from the AD/PD 2026 Conference, Lisha Wang, Assistant Professor at Karolinska Institutet in Stockholm, presents a project developing novel small molecules that promote targeted degradation of tau by engaging the brain’s clearance machinery.

Lisha Wang

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top